The global size of Robotic Radiotherapy Market in terms of revenue was estimated to be worth $1.1 billion in 2023 and is poised to reach $1.9 billion by 2028, growing at a CAGR of 11.9% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

The market's expansion is driven by several factors, including the global rise in cancer cases, advancements in automation technologies enhancing the precision of radiotherapy, a growing preference for non-invasive cancer treatments, and the rapid proliferation of cancer treatment facilities. Additionally, increased merger and acquisition activities between manufacturers and radiotherapy software developers are expected to stimulate the uptake of radiotherapy systems. An illustrative example is the collaboration between GE Healthcare (US) and RaySearch Laboratories (Sweden) in May 2022 to pioneer a novel radiation therapy simulation and treatment planning workflow solution.

Download a FREE Sample PDF of the Global Robotic Radiotherapy Market Research Report at https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122256158

Furthermore, heightened government and private investments aimed at addressing the escalating need for cancer treatment, coupled with the rising healthcare expenditure and the burgeoning medical tourism sector in developing nations, are expected to present attractive growth prospects for stakeholders in the market in the foreseeable future.

Nevertheless, the substantial expense associated with radiotherapy systems may limit their availability in cancer centers, particularly in low-resource economies. Moreover, a scarcity of adequately trained personnel and the intricate nature of radiotherapy systems are anticipated to impede market expansion.

By product, the radiotherapy systems segment accounted for the largest share of robotic radiotherapy industry during the forecast period.

Based on the product, the robotic radiotherapy market is segmented into radiotherapy systems, software, 3D cameras, and others. The software segment accounted for the largest share of the global robotic radiotherapy market in 2022. Rapid penetration of AI in radiotherapy , increasing availability of radiation therapy software, and growing focus of market player on partnership collaboration to enhance radiation software capabilities is supporting the overall growth of segment.

By technology, the linear accelerators segment accounted for the largest share of robotic radiotherapy industry during the forecast period.

Based on technology, the robotic radiotherapy market is segmented into linear accelerators, stereotactic radiation therapy systems, and particle therapy. The linear accelerators segment is expected to account for the for thelargest share of robotic radiotherapy market owing to the availability of advanced systems and their growing adoption worldwide. Furthermore, oncologists are increasingly recognizing the advantages of MR LINAC, leading to heightened investments in research and development for automated LINAC technology. Collaborations between industry players and cancer institutes are also on the rise, aimed at fostering innovation and improving the accessibility of LINAC technology.

By application, lung cancer is expected to witness significant growth of robotic radiotherapy industry during the forecast period.

Based on application, the robotic radiotherapy market is segmented into prostate cancer, breast cancer, lung cancer, head neck cancer, colorectal cancer, and other cancers. The lung cancer segment accounted for the largest share of the global robotic radiotherapy market in 2022. The rapid rise in lung cancer prevalence, coupled with a rising count of patients opting for radiotherapy, is expected to drive growth in this segment. As per the American Lung Association (ALA), approximately 237,000 individuals in the United States received a lung cancer diagnosis in 2022.

By End User, hospital segment to dominate robotic radiotherapy industry end user.

Based on end-user, the global robotic radiotherapy market is segmented into hospitals and independent radiotherapy centers. The Hospitals segment dominated the global robotic radiotherapy end-user market in 2022 owing to the increase in the cancer patients undergoing radiotherapy treatment in cancer hospitals, increasing partnerships between radiotherapy providers and hospitals, and the expansion of cancer hospitals in both developed and developing countries.

Direct Purchase of the Global Robotic Radiotherapy Market Research Report at https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=122256158

North America to account for the largest share of robotic radiotherapy industry during the forecast period.

North America is the expected largest regional market for robotic radiotherapy products in the forecast period. Countries in this market are witnessing a high volume of radiotherapy procedures, robust healthcare infrastructure, extensive patient base, and continuous hospital investments in upgrading their facilities. These elements collectively contribute to the region's significant share in the field.

As of 2022, prominent players in the robotic radiotherapy market are Siemens Healthcare GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA (Belgium), ViewRay Technologies, Inc. (US), C-RAD (Sweden), IBA Worldwide (Belgium), Hitachi Ltd. (Japan (US), Mevion Medical Systems (US), Optivus Proton Therapy, Inc. (US), Panacea Medical Technologies Pvt. Ltd. (India) and P-Cure (Israel), among others.